Loading stock data…
$9.66-0.11 (-1.18%)
Design Therapeutics, Inc.
Design Therapeutics, Inc. in the Healthcare sector is trading at $9.66 with a market capitalization of $941M. Wall Street consensus targets $21.71 (7 analysts), implying a +124.7% move over the next 12 months. The stock is currently 44% below its 52-week high of $17.25, remaining 20.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.18M↓ | -$19.71M↓ | -$18.17M↑ | -$19.31M↑ | -$21.57M |
| Net Income | -$20.16M↓ | -$17.64M↓ | -$16.00M↑ | -$17.00M↑ | -$19.08M |
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platfo...